Psychemedics Corp. (OQ:PMD)

Business Focus: Medical & Diagnostic Laboratories

Mar 28, 2024 08:20 am ET
Psychemedics Corporation Reports 2023 Financial Results
Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact...
Mar 21, 2024 09:00 am ET
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade...
Jan 02, 2024 11:27 am ET
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering...
Nov 27, 2023 09:00 am ET
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for...
Nov 09, 2023 05:00 pm ET
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was...
Oct 27, 2023 11:00 am ET
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform...
Sep 21, 2023 05:00 pm ET
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the...
Aug 18, 2023 02:00 pm ET
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into...
Aug 11, 2023 05:10 pm ET
Psychemedics Corporation Reports Second Quarter 2023 Financial Results
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended June 30, 2023, was...
Jul 12, 2023 05:15 pm ET
Psychemedics Corporation Announces CEO Succession Plan
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today that its board of directors has approved a transition plan for the Company’s President and CEO position. Effective August 17th,...
May 09, 2023 05:30 pm ET
Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be...
Mar 21, 2023 05:15 pm ET
Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash Dividend
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2022. The Company also announced a quarterly...
Nov 09, 2022 05:00 pm ET
Psychemedics Corporation Reports Third Quarter 2022 Financial Results and Declares Quarterly Cash Dividend
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2022. The Company also announced a cash quarterly dividend of $0.07...
Aug 09, 2022 05:15 pm ET
Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2022. The Company also announced a quarterly dividend of $0.07 per...
Jun 09, 2022 05:00 pm ET
Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.’s Retirement after More than 20 Years of Dedicated Service
Psychemedics Corporation (NASDAQ: PMD) announced today that it will be nominating Peter H. Kamin and Darius G. Nevin to serve as new members of its Board of Directors at its upcoming Annual Meeting of Stockholders to be held on August 12, 2022, and...
May 10, 2022 05:15 pm ET
Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per share to be...
Mar 29, 2022 05:15 pm ET
Psychemedics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2021. The Company’s revenue for the year...
Mar 22, 2022 08:30 am ET
Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role
Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew “Drew” M. Reynolds to the Psychemedics Board of Directors effective April 4th, 2022. Mr. Reynolds will also serve...
Dec 10, 2021 05:00 pm ET
Psychemedics Corporation Declares Cash Dividend
Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced that it has declared a cash dividend of $0.05 per share to be paid on December 30th, 2021 to shareholders of record as of...
Nov 12, 2021 05:00 pm ET
Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021
Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2021. The Company’s revenue for the quarter ended September 30,...
Aug 10, 2021 05:10 pm ET
Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results
Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021. The Company’s revenue for the quarter ended June 30, 2021, was...
May 10, 2021 05:15 pm ET
Psychemedics Corporation Reports First Quarter 2021 Financial Results
Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021. The Company’s revenue for the quarter ended March 31, 2021 was...
Mar 23, 2021 05:15 pm ET
Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results
Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020. The Company's revenue for the year ended...
Mar 17, 2021 02:38 pm ET
Robyn C. Davis Joins Psychemedics Board of Directors
Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing...
Jan 26, 2021 03:27 pm ET
Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller
Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller. In this important role, Andrew will be responsible for directing and managing all of the Company’s financial activities...
Dec 17, 2020 10:31 am ET
Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel
Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel. In this important role, Sarah will be responsible for directing and managing all of the company’s legal activities. She...
Nov 09, 2020 05:29 pm ET
Psychemedics Announces Third Quarter Results
Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020. The Company’s revenue for the quarter ended September 30, 2020 was $5.2 million versus $9.9 million for the quarter...
Aug 12, 2020 05:20 pm ET
Psychemedics Announces Second Quarter Results
Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020.  The Company’s revenue for the quarter ended June 30, 2020 was $3.3 million versus $9.3 million for the quarter ended June...
May 13, 2020 05:15 pm ET
Psychemedics Announces First Quarter Results
Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2020.  The Company’s revenue for the quarter ended March 31, 2020 was $7.5 million versus $9.8 million for the quarter ended March...
May 05, 2020 08:00 am ET
Psychemedics Announces a “Vaping Panel” to Detect and Deter the Use of Marijuana, CBD and Nicotine
Psychemedics Corporation (NASDAQ:PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced a Vaping Panel to detect the use of Marijuana, CBD and Nicotine. This test provides a way for schools and...
Apr 29, 2020 12:00 pm ET
Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA
Psychemedics Corporation (NASDAQ:PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine.  This test provides a way...
Apr 28, 2020 02:00 pm ET
Psychemedics Corporation to Webcast 2020 Annual Meeting of Stockholders
Psychemedics Corporation (NASDAQ: PMD) will hold its Annual Meeting of Stockholders (“Annual Meeting”) on Thursday, May 14, 2020 at 2:00 p.m. ET. The meeting, which will be held in a virtual format only, will be webcast to the public and can be...
Feb 11, 2020 05:25 pm ET
Psychemedics Corporation Announces 4th Quarter and Year-End Results
Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of...
Oct 31, 2019 12:07 pm ET
Psychemedics Corporation Responds to Court Decision
Psychemedics Corporation (NASDAQ:PMD) today issued a response to a Massachusetts Supreme Judicial Court ruling in the case of Boston Police Department v. The Massachusetts Civil Service Commission, which dealt with the Boston Police Department’s...
Oct 22, 2019 05:25 pm ET
Psychemedics Announces Third Quarter Results and Declares 93rd Consecutive Quarterly Dividend
Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of November 5,...
Sep 19, 2019 05:25 pm ET
Psychemedics Corporation Announces New Brazilian Distribution Agreement
Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with Toxicologia Pardini Ltda., our existing independent distributor in Brazil, formerly known as...
Jul 23, 2019 05:25 pm ET
Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend
Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 6, 2019,...
Apr 24, 2019 08:00 am ET
Psychemedics Test for Fentanyl Detection Cleared by FDA
Psychemedics Corporation (NASDAQ:PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the industry’s first and only FDA-cleared hair test for Fentanyl, a major killer increasingly found in illegal...
Apr 23, 2019 05:25 pm ET
Psychemedics Announces First Quarter Results and Declares 91st Consecutive Quarterly Dividend
Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of May 7, 2019, to...
Mar 27, 2019 01:46 pm ET
New Psychemedics Offering Further Enhances Cocaine Detection
Psychemedics Corporation (NASDAQ:PMD), the world leader in detecting drugs of abuse using hair analysis, today at the National Drug and Alcohol Screening Association (NDASA) Conference introduced the industry’s first confirmation process to...
Mar 04, 2019 05:15 pm ET
Psychemedics Corporation Announces 3rd Straight Year of Record Revenue; Declares 90th Consecutive Quarterly Dividend
Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2018. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of...
Nov 15, 2018 07:30 am ET
New Research Coverage Highlights The Dixie Group, 500, Valhi, Ikonics, CSP, and Psychemedics — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Dixie Group, Inc. (NASDAQ:DXYN), 500.com Limited (NYSE:WBAI), Valhi,...
Oct 23, 2018 05:30 pm ET
Psychemedics Announces Quarterly Results
Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of November 2,...
Jul 24, 2018 05:30 pm ET
Psychemedics Announces 2Q Record Revenues
Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2018.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 7, 2018,...
May 08, 2018 10:00 am ET
James Abely Promoted to VP and General Counsel at Psychemedics Corporation
Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair analysis drug testing, today announced that James Abely has been promoted to the position of Vice President and General Counsel. In this important role, Jim is responsible...
May 02, 2018 01:00 pm ET
Psychemedics Corporation Announces New Vice President, Sales and Marketing
Psychemedics Corporation (NASDAQ:PMD) announced the appointment of Charles M. Doucot as the Company's Vice President, Sales and Marketing.  Mr. Doucot will be responsible for global sales and marketing activities and be a key member of the...
Apr 24, 2018 05:15 pm ET
Psychemedics Announces 1Q Record Revenues and Dividend Increase of 20%
ACTON, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2018.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders...
Mar 07, 2018 05:00 pm ET
Psychemedics Corporation Announces Q4 and Year End Results
Declares 86th Consecutive Quarterly Dividend
Oct 24, 2017 06:00 pm ET
Psychemedics Corporation Announces Q3 Earnings
ACTON, Mass., Oct. 24, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2017.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 6, 2017, to be paid on November 17, 2017.  This will be the Company's 85th consecutive quarterly dividend.
Sep 26, 2017 03:30 pm ET
Psychemedics Announces Addition of FDA-Cleared Benzodiazepines Hair Test
ACTON, Mass., Sept. 26, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ:PMD), hair testing pioneer and global leader for over thirty years, announced the launch of its FDA-Cleared Benzodiazepines hair test.  The test detects numerous Benzodiazepines, including Xanax®, Valium®, and Ativan®, and is available as a stand-alone test or as an option on Psychemedics' standard drug panels.
Aug 22, 2017 03:00 pm ET
Psychemedics Corporation Launches Synthetic Cannabinoids Hair Test
ACTON, Mass., Aug. 22, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD), hair testing pioneer and global scientific leader for over thirty years, announced the launch of its Synthetic Cannabinoids test – a hair test that looks for the compounds found in commonly-abused products such as K2, Spice and Blaze.
Aug 16, 2017 02:00 pm ET
Psychemedics Corporation - First Lab Approved For Hair Testing In Iowa
ACTON, Mass., Aug. 16, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced it has become the first laboratory to be approved for the testing of drugs of abuse in hair by the State of Iowa. 
Aug 02, 2017 05:30 pm ET
Psychemedics Corporation Announces Q2 Earnings
ACTON, Mass., Aug. 2, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2017.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 14, 2017, to be paid on August 24, 2017.  This will be the Company's 84th consecutive quarterly dividend.
Apr 25, 2017 06:00 pm ET
Psychemedics Corporation Announces Record Q1 Revenues And Earnings
ACTON, Mass., April 25, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2017.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 8, 2017, to be paid on May 18, 2017.  This will be the Company's 83rd consecutive quarterly dividend.
Mar 29, 2017 05:18 pm ET
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Psychemedics Corporation To C
STEVENSON, Md., March 29, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plai...
Mar 28, 2017 03:00 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Psychemedics Corporation - PMD
NEW YORK, March 28, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Psychemedics Corporation securities (NASDAQ: PMD) from February 28, 2014 through January 30, 2017, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Psychemedics investors under the federal securities laws.
Mar 26, 2017 03:31 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Psychemedics Corporation Of Imminent Lead Plaintiff Deadline
NEW YORK, March 26, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Psychemedics Corporation ("Psychemedics" or the "Company") (NASDAQ: PMD) of the April 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
Mar 21, 2017 12:40 pm ET
Mar 17, 2017 07:41 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Psychemedics Corporation of Class Action Lawsuit and Upcoming Deadline – PMD
NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers.   The class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of investors who purchased or otherwise acquired Psychemedics securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934....
Mar 17, 2017 12:20 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Psychemedics Corporation
NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
Mar 15, 2017 08:47 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Psychemedics Corporation To Contact The Firm Before Lead Plaintiff Deadline
NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) of the April 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers....
Mar 13, 2017 05:53 pm ET
ALERT: Rosen Law Firm Reminds Psychemedics Corporation Investors of Important Deadline in Class Action – PMD
NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Psychemedics Corporation securities (NASDAQ:PMD) from February 28, 2014 through January 30, 2017, inclusive (the “Class Period”) of the important April 3, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Psychemedics investors under the federal securities laws....
Mar 03, 2017 12:06 pm ET
PMD INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Psychemedics Corporation and a Lead Plaintiff Deadline of April 3, 2017
NEW YORK, March 3, 2017 /PRNewswire-USNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Psychemedics Corporation (NASDAQ: PMD) securities between February 28, 2014 and January 30, 2017.
Feb 27, 2017 06:05 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Psychemedics Corporation – PMD
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Psychemedics Corporation securities (NASDAQ:PMD) from February 28, 2014 through January 30, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Psychemedics investors under the federal securities laws....
Feb 27, 2017 02:28 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Psychemedics Corporation (PMD) To Contact Brower Piven Before The Lead Plaintiff Deadline
STEVENSON, Md., Feb. 27, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plainti...
Feb 17, 2017 08:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Psychemedics Corporation of Class Action Lawsuit and Upcoming Deadline – PMD
NEW YORK, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers.   The class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of investors who purchased or otherwise acquired Psychemedics securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934....
Feb 17, 2017 10:54 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Psychemedics Corporation
NEW YORK, Feb. 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
Feb 10, 2017 06:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Psychemedics Corporation of Class Action Lawsuit and Upcoming Deadline - PMD
NEW YORK, Feb. 10, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Psychemedics Corporation ("Psychemedics" or the "Company") (NASDAQ:  PMD) and certain of its officers.   The class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of investors who purchased or otherwise acquired Psychemedics securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.
Feb 09, 2017 05:00 pm ET
IMPORTANT PSYCHEMEDICS CORPORATION INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of Massachusetts against P
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action was filed against Psychemedics Corporation (NASDAQ:PMD) (“Psychemedics” or the “Company”) in the United States District Court for the District of Massachusetts. The complaint is brought on behalf of all purchasers of Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (“Class Period”)....
Feb 07, 2017 01:50 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Psychemedics Corporation (PMD) & Lead Plaintiff Deadline: April 3, 2017
NEW YORK, Feb. 7, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Psychemedics Corporation ("Psychemedics" or the "Company") (NASDAQ: PMD) and certain of its officers, on behalf of a class who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pmd.
Feb 06, 2017 04:15 pm ET
Psychemedics Corporation Announces Record Revenues And Earnings
ACTON, Mass., Feb. 6, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2016.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 16, 2017 to be paid on February 27, 2017.  This will be the Company's 82nd consecutive quarterly dividend.
Feb 06, 2017 08:46 am ET
Johnson & Weaver, LLP Announces Investigations of Stemline Therapeutics, Inc., Psychemedics Corporation and Ultratech, Inc.
SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Stemline Therapeutics, Inc., Psychemedics Corporation and Ultratech, Inc., as detailed below:
Feb 03, 2017 02:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Psychemedics Corporation and Certain Officers – PMD
NEW YORK, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ:PMD) and certain of its officers.  The class action, filed in United States District Court, District of Massachusetts, is on behalf of a class consisting of investors who purchased or otherwise acquired Psychemedics securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934....
Feb 03, 2017 10:01 am ET
EQUITY ALERT: Rosen Law Firm Continues Investigation of Securities Claims Against Psychemedics Corporation - PMD
NEW YORK, Feb. 3, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of Psychemedics Corporation (NASDAQ: PMD) resulting from allegations that Psychemedics may have issued materially misleading business information to the investing public.
Feb 02, 2017 03:16 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Files in U.S. District Court to Recover Losses Suffered by Investors in Psychemedics Corporation
NEW YORK, Feb. 02, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:...
Feb 01, 2017 06:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Psychemedics Corporation - PMD
NEW YORK, Feb. 1, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Psychemedics Corporation ("Psychemedics" or the "Company") (NYSE: PMD).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Feb 01, 2017 11:59 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Psychemedics Corporation -- PMD
NEW YORK, Feb. 1, 2017 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Psychemedics Corporation (NASDAQ: PMD) concerning possible violations of federal securities laws.
Jan 31, 2017 03:40 pm ET
Psychemedics Corporation Responds To Recent Price Volatility
ACTON, Mass., Jan. 31, 2017 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced that recent volatility in its stock price on January 31, 2017 appears to have been caused by a news report of a court ruling in Brazil involving Psychemedics Brasil. 
Jan 31, 2017 01:58 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Psychemedics Corporation (PMD)
NEW YORK, Jan. 31, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Psychemedics Corporation ("Psychemedics" or the "Company") (NASDAQ: PMD). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pmd.
Jan 31, 2017 01:45 pm ET
PSYCHEMEDICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Psychemedics Corporation To Contact The Firm
NEW YORK, Jan. 31, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Psychemedics Corporation ("Psychemedics" or the "Company") (NASDAQ: PMD).
Oct 26, 2016 05:30 pm ET
Psychemedics Corporation Announces Record Revenues and Earnings
ACTON, Mass., Oct. 26, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced third quarter financial results for the period ended September 30, 2016.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of November 7, 2016 to be paid on November 17, 2016.  This will be the Company's 81st consecutive quarterly dividend.
Sep 13, 2016 06:24 pm ET
Psychemedics Corporation Earns Prestigious Recognition for Superior Customer Service
ACTON, Mass., Sept. 13, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD), the world's leading and largest hair analysis drug testing company, announced that it has been certified as a Center of Excellence by BenchmarkPortal. The Center of Excellence recognition is one of the most prestigious awards in the customer service and support industry.
Jul 26, 2016 05:30 pm ET
Psychemedics Corporation Announces Record Revenues And Earnings
ACTON, Mass., July 26, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2016.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 5, 2016 to be paid on August 15, 2016.  This will be the Company's 80th consecutive quarterly dividend.
Jun 22, 2016 06:00 pm ET
James P. Abely Joins Psychemedics Corporation as Associate General Counsel
ACTON, Mass., June 22, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) announced that James P. Abely has joined the company as Associate General Counsel.
Apr 26, 2016 06:45 pm ET
Psychemedics Corporation Announces Quarterly Results
ACTON, Mass., April 26, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2016.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 6, 2016 to be paid on May 18, 2016.  This will be the Company's 79th consecutive quarterly dividend.
Feb 10, 2016 05:20 pm ET
Psychemedics Corporation Announces Quarterly And Annual Results
ACTON, Mass., Feb. 10, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2015. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 22, 2016 to be paid on March 4, 2016. This will be the Company's 78th consecutive quarterly dividend.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.